William Blair & Company
TLX

William Blair & Company’s Telix Pharmaceuticals TLX Stock Holding History

William Blair & Company’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
+122,985
New +$1.25M ﹤0.01% 867
2025
Q3 		– Sell
-13,500
Closed -$217K – 1919
2025
Q2 		$217K Buy
+13,500
New +$227K ﹤0.01% 1390

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

William Blair & Company's TLX Position: Q2 2026 in Review

William Blair & Company opened a new position in Telix Pharmaceuticals (TLX) in Q2 2026: 122,985 shares worth $1.42M. The stake represents ﹤0.01% of the portfolio and ranks #867 among its holdings. This is a return to the name: William Blair & Company previously reported a position in TLX as recently as Q2 2025.

William Blair & Company first reported a position in TLX in Q2 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • William Blair & Company held 122,985 shares of Telix Pharmaceuticals worth $1.42M as of Q2 2026.
  • Telix Pharmaceuticals was a new William Blair & Company position in Q2 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #867 holding.
  • William Blair & Company first reported a position in Telix Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.